224441-73-0

Basic information

• Product Name: Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)-
• Synonyms: 5-tert-Butyl-2-chloromethyloxazole
• CAS NO: 224441-73-0
• Molecular Formula: C₈H₁₂ClNO
• Molecular Weight: 173.64
• Mol File: 224441-73-0.mol

Chemical Properties

• Boiling Point: 204.772 °C at 760 mmHg
• Flash Point: 77.644 °C
• Appearance: /
• Density: 1.086 g/cm³
• Vapor Pressure: 0.37mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: 2-8°C
• PKA: 1.33±0.42(Predicted)
• CAS DataBase Reference: Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)-(224441-73-0)
• EPA Substance Registry System: Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)-(224441-73-0)

Safety Data

• RIDADR: UN1760
• Hazardous Substances Data: 224441-73-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)is used as an intermediate compound for the synthesis of various pharmaceuticals. Its distinctive molecular structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicine.
Used in Agrochemical Industry:
Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)is also utilized as a building block in the creation of agrochemicals. Its presence in the molecular structure of certain agrochemicals can enhance their effectiveness in pest control and crop protection, thereby supporting agricultural productivity.
Used in Dye Industry:
Oxazole,2-(chloromethyl)-5-(1,1-dimethylethyl)is employed as a chemical constituent in the formulation of dyes. Its incorporation into dye molecules can improve the colorfastness and stability of the dyes, making them more suitable for various applications in the textile and other industries.

InChI:InChI=1/C8H12ClNO/c1-8(2,3)6-5-10-7(4-9)11-6/h5H,4H2,1-3H3

Upstream product

• 333389-44-9 α-N-2-(chloroacetylamino)pinacolone 
• 6832-15-1 1-diazo-3,3-dimethyl-2-butanone 
• 144-55-8 sodium hydrogencarbonate 
• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 1634-04-4 tert-butyl methyl ether 
• 3282-30-2 pivaloyl chloride 
• 33119-72-1 1-amino-3,3-dimethylbutan-2-one hydrochloride 
• 5469-26-1 1-Bromopinacolon 
• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 1012059-88-9 methyl 4-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)butanoate 
• 1012059-90-3 methyl-5-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)-thiazol-2-ylamino)-2-oxoethyl)phenoxy)pentanoate 
• 1133000-56-2 (E)-ethyl 3-(4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-carbamoyl)phenyl)acrylate 
• 1133001-82-7 methyl 4-(3-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-amino)-2-oxoethyl)phenoxy)butanoate 
• 1133001-42-9 methyl 4-(4-(1-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-1-oxopropan-2-yl)phenoxy)butanoate 
• 1133001-28-1 ethyl 4-(4-(3-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)ureido)phenoxy)butanoate 
• 1133001-19-0 ethyl 4-(4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylcarbamoyloxy)phenoxy)butanoate 
• 1133000-87-9 methyl 3-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)propanoate 
• 1133001-16-7 methyl 4-(4-(1-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-methyl-1-oxopropan-2-yl)phenoxy)butanoate 
• 1133001-45-2 (E)-methyl 3-(3-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)-sulfamoyl)phenyl)acrylate 
• 1133001-58-7 methyl 4-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)sulfamoyl)benzoate 
• 1133001-70-3 (E)-methyl 3-(4-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)-sulfamoyl)phenyl)acrylate 
• 1133000-85-7 3-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)-thiazol-2-ylamino)-2-oxoethyl)phenoxy)-N-hydroxypropanamide 
• 1012056-34-6 4-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)-N-hydroxybutanamide 

Relevant articles and documents

Nitrogen Mustard Derivatives

The disclosure includes compounds of Formula (1): wherein X1, X2, Q, Z, R1, and R2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

CDK INHIBITORS

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl] -4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

N-Acyl-2-aminothiazoles with nonaromatic acyl side chains containing a basic amine were found to be potent, selective inhibitors of CDK2/cycE which exhibit antitumor activity in mice. In particular, compound 21 {N-[5-[[[5-(1,1-dimethylethyl)-2- oxazolyl]m

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

The present invention describes compounds of formula I: and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for exam

Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy

The invention provides a method for preventing or treating alopecia induced by chemotherapy or radiotherapy by administering to a mammalian specie in need thereof a therapeutically effective amount of a compound of formula I or II or a pharmaceutically ac

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, x-ray crystallographic analysis, and biological activities

High throughput screening identified 2-acetamido-thiazolylthio acetic ester 1 as an inhibitor of cyclin-dependent kinase 2 (CDK2). Because this compound is inactive in cells and unstable in plasma, we have stabilized it to metabolic hydrolysis by replacing the ester moiety with a 5-ethyl-substituted oxazole as in compound 14. Combinatorial and parallel synthesis provided a rapid analysis of the structure-activity relationship (SAR) for these inhibitors of CDK2, and over 100 analogues with IC50 values in the 1-10 nM range were rapidly prepared. The X-ray crystallographic data of the inhibitors bound to the active site of CDK2 protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues displayed potent and broad spectrum antiproliferative activity across a panel of tumor cell lines in vitro. In addition, A2780 ovarian carcinoma cells undergo rapid apoptosis following exposure to CDK2 inhibitors of this class. Mechanism of action studies have confirmed that the phosphorylation of CDK2 substrates such as RB, histone H1, and DNA polymerase α (p70 subunit) is reduced in the presence of compound 14. Further optimization led to compounds such as water soluble 45, which possesses a favorable pharmacokinetic profile in mice and demonstrates significant antitumor activity in vivo in several murine and human models, including an engineered murine mammary tumor that overexpresses cyclin E, the coactivator of CDK2.

Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy

The invention provides a method for preventing or treating alopecia induced by chemotherapy or radiotherapy by administering to a mammalian specie in need thereof a therapeutically effective amount of a compound of formula I or II or a pharmaceutically ac

Aminothiazole inhibitors of cyclin dependent kinases

Compounds of the formula and pharmaceutically acceptable salts thereof. R1and R2are independently hydrogen, fluorine or alkyl; R3is aryl or heteroaryl R4is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, he